Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU.

Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150.

2.
3.
4.

Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.

Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU.

Schizophr Res. 2016 Oct;176(2-3):220-30. doi: 10.1016/j.schres.2016.07.018.

PMID:
27499361
5.
6.

Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.

Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU.

J Clin Psychiatry. 2013 Oct;74(10):957-65. doi: 10.4088/JCP.13r08440.

PMID:
24229745
7.
8.
9.

Long-acting injectable antipsychotics: evidence of effectiveness and use.

Manchanda R, Chue P, Malla A, Tibbo P, Roy MA, Williams R, Iyer S, Lutgens D, Banks N.

Can J Psychiatry. 2013 May;58(5 Suppl 1):5S-13S. Review.

PMID:
23945067
10.
11.
12.

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.

Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Curr Med Res Opin. 2014 Aug;30(8):1643-55. doi: 10.1185/03007995.2014.915211. Review.

PMID:
24730586
13.

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.

Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU.

Mol Psychiatry. 2013 Jan;18(1):53-66. doi: 10.1038/mp.2011.143. Review.

14.

Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).

Novakovic V, Adel T, Peselow E, Lindenmayer JP.

Clin Neuropharmacol. 2013 Mar-Apr;36(2):59-62. doi: 10.1097/WNF.0b013e3182854f70. Review.

PMID:
23503549
15.

Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials.

Kishi T, Oya K, Iwata N.

Int J Neuropsychopharmacol. 2016 Sep 21;19(9). pii: pyw038. doi: 10.1093/ijnp/pyw038.

16.

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.

Sampford JR, Sampson S, Li BG, Zhao S, Xia J, Furtado VA.

Cochrane Database Syst Rev. 2016 Jul 2;7:CD010832. doi: 10.1002/14651858.CD010832.pub2. Review.

PMID:
27370402
17.

Risperidone (depot) for schizophrenia.

Sampson S, Hosalli P, Furtado VA, Davis JM.

Cochrane Database Syst Rev. 2016 Apr 14;4:CD004161. doi: 10.1002/14651858.CD004161.pub2. Review.

PMID:
27078222
18.

[Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].

Graffino M, Montemagni C, Mingrone C, Rocca P.

Riv Psichiatr. 2014 May-Jun;49(3):115-23. doi: 10.1708/1551.16905. Review. Italian.

PMID:
25000887
19.

Fluphenazine decanoate (depot) and enanthate for schizophrenia.

Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE.

Cochrane Database Syst Rev. 2015 Feb 5;(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Review.

PMID:
25654768
20.

Depot fluphenazine decanoate and enanthate for schizophrenia.

David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD000307. Review. Update in: Cochrane Database Syst Rev. 2015;2:CD000307.

PMID:
15674872
Items per page

Supplemental Content

Support Center